These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31347685)

  • 41. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanism-based design of agents that selectively target drug-resistant glioma.
    Lin K; Gueble SE; Sundaram RK; Huseman ED; Bindra RS; Herzon SB
    Science; 2022 Jul; 377(6605):502-511. PubMed ID: 35901163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 45. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
    Wu H; Li X; Zhang T; Zhang G; Chen J; Chen L; He M; Hao B; Wang C
    Neuromolecular Med; 2020 Sep; 22(3):359-369. PubMed ID: 32086739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
    Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
    Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
    Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
    Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
    Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
    Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
    Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
    Nie E; Jin X; Miao F; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Xie M; You Y
    Neuro Oncol; 2021 Mar; 23(3):435-446. PubMed ID: 32813021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma.
    Wu Q; Berglund AE; Wang D; MacAulay RJ; Mulé JJ; Etame AB
    Sci Rep; 2019 Oct; 9(1):14072. PubMed ID: 31575897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
    Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.